Jeffrey Gross, PhD, joins Angiotech Pharmaceuticals as Vice President of Engineering
Life Science Partner recruits former Group Director, Biologics Research and Development of Medtronic Sofamor Danek.
Life Science Partner announces the recruitment of Jeffrey Gross, PhD, former Group Director of Biologics R & D at Medtronic Sofamor Danek in Memphis, Tennessee, as Vice President of Engineering. Angiotech is the world leader in the emerging field of drug-eluting medical devices and biomaterials. With an accelerated program to integrate pharmaceutical and biologically active materials to improve its products, Gross will lead the discovery team to capitalize upon Angiotech’s considerable intellectual property portfolio to create breakthrough products.
In Jeff’s previous role at Medtronic, he led large multidisciplinary teams of scientists and engineers in the development of heart valves and, more recently, in innovative, next-generation biological products for spine and cranial surgeons.
“Jeff has a broad cardiovascular product background and is well-grounded in biological and mechanical medical device development,” noted Tom Callaway, MD, founder and president of Life Science Partner. “He knows how to lead cross-functional teams across multiple technologies to bridge the combination product development divide successfully.”
In his role as Vice President of Engineering, Jeff will provide strategic and tactical direction for engineering R & D across multiple complex device platforms within numerous sites and divisions of Angiotech. His teams will bridge the continuum from product concept through design review phases, and pilot manufacturing and transfer.
Jeff earned his B.S. in Mechanical Engineering at the Georgia Institute of Technology and his M.S in Biomedical Engineering from the University of Houston. He received his PhD in Biomedical Engineering (Biofluid Mechanics) from the University of Memphis in Memphis, Tennessee.
Leave a ReplyWant to join the discussion?
Feel free to contribute!